Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Elucidating a Novel Mechanism for LATS1/2 in Suppressing Tumorigenesis

Award Number: R00CA259329
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2021
PERIOD OF PERFORMANCE END DATE: 05/31/2025

Group Awards By:

View Award Description

Elucidating a Novel Mechanism for LATS1/2 in Suppressing Tumorigenesis - Abstract: The Hippo pathway is an evolutionarily conserved signaling cascade regulating numerous biological processes, including cell growth and fate decision, organ size control, and regeneration. The core of the Hippo pathway in mammals consists of a kinase cascade, LATS1/2 and MST1/2 that controls various cellular processes through orchestrating the phosphorylation of downstream substrates including YAP and TAZ. In keeping with a possible tumor suppressive role of the Hippo signaling pathway, it has been found that Hippo pathway dysregulation is common in many human tumors including breast, glioma, lung, colorectal cancer, and endometrial cancer. However, although a few of upstream regulators and downstream substrates were identified, the exact molecular mechanisms underlying how upstream signaling pathways control LATS1/2 kinase activity and its physiological functions in breast cancer have not yet been fully elucidated. Hence, the major goal of this proposal is to explore the upstream regulator of LATS1/2 as well as to uncover a novel tumor suppressor role of LATS1/2 in controlling tumorigenesis in the breast cancer setting. To this end, I have obtained preliminary data showing that the deubiquitinating enzyme OTUD3, but not other OTUD family member, specifically interacts and deubiquitinates LATS1. More importantly, I identified Raptor, one of the core components of mTORC1 which is a central cell growth regulator governing cellular metabolism, as a novel phosphorylation substrate of LATS1/2. In this proposal, I plan to: 1) characterize OTUD3 as a novel upstream regulator that positively regulates LATS1/2 kinase activity largely through deubiquitination of LATS1/2; 2) determine the physiological role of LATS1/2 in suppressing breast tumorigenesis largely through phosphorylating Raptor at Ser606 site, which in turn inhibits the kinase activity of mTORC1; 3) determine whether and how Raptor phosphorylation at Ser606 by LATS1/2 regulates breast cancer development in vivo. The long-term goals of my career are to apply the insights of molecular and cellular biology studies to understand the physiological significance of deregulated Hippo/mTORC1 signaling pathways that are important in the development of human malignancies, especially in breast cancer, and to search for proper druggable targets for better anti-breast cancer treatment. This K99/R00 award will provide protected time for me to pursue the novel hypotheses of this proposal, obtain new skill sets to execute experiments and solve problems. In addition, the K99 award will allow me to focus my efforts on independently conducting basic and translational research, and to train future young scientists in the cancer biology field.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$73,437 )
2026	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	000	5	11/18/2025	NON-COMPETING CONTINUATION	-$73,437
														Subtotal = -$73,437

Issue Date FY: 2025 ( Subtotal = $249,000 )
2025	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	002	5	6/24/2025	NON-COMPETING CONTINUATION	$0
2025	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	001	5	5/22/2025	NON-COMPETING CONTINUATION	$24,899
2025	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	000	5	2/13/2025	NON-COMPETING CONTINUATION	$224,101
														Subtotal = $249,000

Issue Date FY: 2024 ( Subtotal = $249,000 )
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	001	4	4/16/2024	NON-COMPETING CONTINUATION	$24,899
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	000	4	2/23/2024	NON-COMPETING CONTINUATION	$224,101
														Subtotal = $249,000

Issue Date FY: 2023 ( Subtotal = $249,000 )
2023	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	001	3	9/21/2023	EXTENSION WITH OR WITHOUT FUNDS	$0
2023	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	000	3	8/15/2023	EXTENSION WITH OR WITHOUT FUNDS	$249,000
														Subtotal = $249,000

Grand Total All Awards = $673,563

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Elucidating a Novel Mechanism for LATS1/2 in Suppressing Tumorigenesis

Award Number: R00CA259329

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2021

PERIOD OF PERFORMANCE END DATE: 05/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer